The global biotechnology market is experiencing robust growth, with analysts estimating it at $480–$550 billion in 2024–25 and projecting roughly 13% year-over-year growth into 2026 and 13–14% compound annual growth through 2034, driven by biologics, gene and cell therapies, and personalized medicine. The signals are mixed, though: constrained capital access, higher cost of capital, and rising regulatory complexity are fueling M&A and strategic partnerships as firms scale R&D and manufacturing.
This ETS snapshot identifies the six critical supply chain challenges — cold-chain logistics, raw material shortages and single-source CMO dependencies, serialization and track-and-trace complexity, data visibility gaps between planning, execution, and third-party logistics, fill/finish and biologics scale-up bottlenecks, and logistics disruption risk — and maps each to an SAP cloud solution: SAP Business Network for Logistics with SAP ERP Cloud and EWM, SAP Ariba Supplier Lifecycle, SAP Advanced Track and Trace for Pharmaceuticals, SAP IBP with Analytics Cloud, and manufacturing execution with batch genealogy.
It lays out a phased roadmap — supplier health scoring and critical supplier onboarding in the first three months, IBP demand sensing and safety-stock optimization next, serialization in the highest-risk areas in parallel, then 3PL and carrier connectivity — and recommends prioritizing supplier resilience and demand/supply visibility first because they address the biggest single-point risks and deliver the fastest ROI.
The full snapshot is available above as a PDF. For the complete deck, see "Biotech Supply Chain Revolution" in the Resource Library.